分娩期阿片类药物暴露后产后持续性阿片类药物使用
该回顾性队列研究基于2015-2021年宾夕法尼亚州医疗补助数据,纳入172,839例分娩,评估分娩期阿片暴露与产后持续阿片使用的关系。分娩期阿片暴露率为25%,产后持续使用率为5.7%;暴露者持续使用风险高于未暴露者(aOR 1.88,95%CI 1.79-1.96),曲马多暴露风险最高(aOR 4.58,95%CI 3.87-5.43)。
要点
- 分娩期阿片暴露与产后持续阿片使用相关(aOR 1.88,95%CI 1.79-1.96)。
- 无阿片使用史者中,暴露者持续使用风险仍升高(aOR 2.66,95%CI 2.49-2.85)。
- 曲马多暴露者持续使用风险高于羟考酮暴露者(aOR 4.58,95%CI 3.87-5.43)。
核心结论
- 分娩期阿片暴露与产后持续阿片使用相关,包括无阿片使用史者和无既往疼痛疾病者。
- 研究结果支持平衡有效产后疼痛管理与最小化阿片相关风险的临床实践指南,并强调产后护理协调的重要性。
研究设计与样本
- 回顾性队列研究,使用2015-2021年宾夕法尼亚州医疗补助索赔数据。
- 纳入19-50岁阴道或剖宫产分娩且产后一年内医疗补助参保至少10个月者,共172,839例符合标准。
- 主要暴露为分娩前7天至分娩后8周内填写阿片处方;主要结局为产后持续阿片使用,定义为产后8周至14个月内两个或以上日历季度有阿片使用障碍诊断或至少一次填写阿片处方。
主要发现
- 分娩期阿片暴露存在于25%的分娩中(n=43,263);产后持续阿片使用患病率为5.7%(n=9,876)。
- 分娩期阿片暴露者产后持续使用率为7.9%,未暴露者为4.5%(aOR 1.88,95%CI 1.79-1.96)。
- 在132,941例无阿片使用史者中,2.6%发生产后持续阿片使用;暴露者调整后比值高于未暴露者(aOR 2.66,95%CI 2.49-2.85)。
- 曲马多暴露者中30.9%转为持续使用,羟考酮暴露者中为7.3%(曲马多 vs 羟考酮:aOR 4.58,95%CI 3.87-5.43)。
关键数值与推荐
- 产后持续阿片使用定义为产后8周至14个月内两个或以上日历季度有阿片使用障碍诊断或至少一次填写阿片处方。
- 分娩期阿片暴露定义为分娩前7天至分娩后8周内填写阿片处方。
临床怎么用
- 研究结果支持平衡有效产后疼痛管理与最小化阿片相关风险的临床实践指南,并强调产后护理协调的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the association between opioid exposure in the childbirth period and persistent postpartum opioid use and to evaluate whether there are differential associations based on specific medication exposure. METHODS: Retrospective cohort study that used 2015-2021 Pennsylvania Medicaid claims of women aged 19-50 years with vaginal or cesarean delivery and Medicaid enrollment for at least 10 months during the postpartum year. Primary exposure was filled opioid prescription from 7 days before delivery to 8 weeks after delivery (childbirth period). The main outcome measure was persistent postpartum opioid use , defined as either a diagnosis of opioid use disorder or at least one filled opioid prescription in two or more calendar quarters from 8 weeks to 14 months postpartum. Multivariable logistic regression analyses included demographic information, mental health and behavioral comorbidities, obstetric trauma, and pre-existing pain conditions with subgroup analysis of the prepregnancy opioid-naïve population. RESULTS: Of 286,003 births in the Pennsylvania Medicaid program, 172,839 met inclusion criteria (patient demographics: 41,628 Black [24.1%], 102,733 White [59.4%], 26,841 Hispanic [15.5%], mean age at delivery 26.9 years). Childbirth opioid exposure was present in 25% of births (n=43,263). The prevalence of persistent postpartum opioid use was 5.7% (n=9,876). Transition to postpartum persistent use occurred in 7.9% of patients with childbirth opioid exposure and in 4.5% of those without (adjusted odds ratio [aOR] 1.88, 95% CI, 1.79-1.96). Among 132,941 births to opioid-naïve people, 2.6% of patients developed postpartum persistent opioid use; the adjusted odds were higher among those exposed during childbirth compared with those unexposed (aOR, 2.66; 95% CI, 2.49-2.85). The risk of persistent use was highest with tramadol exposure: 30.9% of people exposed to tramadol transitioned to persistent use compared with 7.3% of those exposed to oxycodone (tramadol vs oxycodone: aOR 4.58; 95% CI, 3.87-5.43). CONCLUSION: Opioid use for childbirth pain management was associated with persistent postpartum use, including among opioid-naïve patients and those without pre-existing pain conditions. These findings support clinical practice guidelines that balance effective postpartum pain management with minimizing opioid-related risks and underscore the importance of postpartum care coordination.
引用
- Matone M, Nguemeni Tiako MJ, Strane D, et al. Postpartum Persistent Opioid Use After Opioid Exposure for Childbirth. Obstet Gynecol. 2025. PMID: 41264916. doi:10.1097/AOG.0000000000006127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。